Provided by Tiger Trade Technology Pte. Ltd.

Immunic, Inc.

14.24
-0.3400-2.33%
Pre-market: 14.250.0100+0.07%08:11 EDT
Volume:225.16K
Turnover:3.25M
Market Cap:193.66M
PE:-3.56
High:15.22
Open:14.70
Low:14.10
Close:14.58
52wk High:17.43
52wk Low:5.06
Shares:13.60M
Float Shares:11.92M
Volume Ratio:1.01
T/O Rate:1.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9979
EPS(LYR):-6.2414
ROE:-138.17%
ROA:-66.80%
PB:1.52
PE(LYR):-2.28

Loading ...

Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans

TIPRANKS
·
Jul 15

Immunic Publishes Investor Presentation Outlining Vidofludimus Calcium Phase 3 Program in Multiple Sclerosis

Reuters
·
Jul 14

Immunic Names CEO Erik Lundgren to Board After Tamar Howson Retirement Resignation

Reuters
·
Jul 07

Immunic Holds Annual Shareholder Meeting, Backs 6 Million-share Increase to Equity Plan

Reuters
·
Jun 30

Immunic joins H.C. Wainwright Neuro Perspectives Expert Summit fireside chat

Reuters
·
Jun 10

Immunic files Form 3 initial beneficial ownership statement for CEO Erik Lundgren

Reuters
·
Jun 02

Immunic publishes investor presentation on oral immunology pipeline led by vidofludimus calcium in multiple sclerosis

Reuters
·
Jun 01

Stifel Nicolaus Reaffirms Their Buy Rating on Immunic (IMUX)

TIPRANKS
·
May 29

Immunic presents new Phase 2 CALLIPER analyses of vidofludimus calcium in progressive multiple sclerosis at CMSC 2026

Reuters
·
May 28

Eqs-News: Immunic to Present Additional Phase 2 Calliper Trial Data for Vidofludimus Calcium at the Cmsc Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis

THOMSON REUTERS
·
May 28

Immunic Appoints New CEO to Lead MS Strategy

TIPRANKS
·
May 27

Immunic names ex-Genentech executive Erik Lundgren CEO, replacing Daniel Vitt

Reuters
·
May 27

Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer

THOMSON REUTERS
·
May 27

Immunic Is Maintained at Buy by B. Riley Securities

Dow Jones
·
May 22

B. Riley cuts Immunic target, sees ‘compelling entry point’

TIPRANKS
·
May 22

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cardiff Oncology (CRDF), ACADIA Pharmaceuticals (ACAD) and Immunic (IMUX)

TIPRANKS
·
May 22

B. Riley Adjusts Price Target on Immunic to $27 From $40, Maintains Buy Rating

MT Newswires Live
·
May 22

Immunic director Michael W. Bonney files initial beneficial ownership statement

Reuters
·
May 20

Immunic names Michael Bonney board chair, replacing interim chair Simona Skerjanec

Reuters
·
May 19

Immunic Inc - Simona Skerjanec Transitions From Interim Chairperson to Board Member

THOMSON REUTERS
·
May 19